Bridging the Gap: Index Volume [International Conference on AIDS (12th: 1998: Geneva, Switzerland)]

200 zymmune zymmune

12th World AIDS Conference

SKeyword Abstrz
HIV infection in Lusaka, /Mycobacterial blood cultures to d
n the era of HIV/AIDS in: Socio-economic factors, cultural
are workers in Lusaka, /Perceived and actual risks of occ
he detribalisation of the Zambian youth and its consequences of HI
AIDs program planning: experience/A new approach to i
ransfusion service the experience/Establishing a natio
DS Prevention Project ( ZAPP ) experience/Challenges in impleme
ated antiviral treatment ZDV-DDC (Retrovir-Hivid) in adult HIV(+)/
s of HIV-1 strains with a ZDV-resistance mutation at codon 215, in
of HIV from patients on ZDV/3TC/amprenavir combination therap
ation with zidovudine ( ZDV/AZT) and zalcitabine (ddC) for HIV/AI
wo trials of ZDV/ddl vs ZDV/ddl/NVP /Patients with higher baselin
two trials of ZDV/ddl vs /Predictors of duration of vir
wo trials of ZDV/ddl vs /Meta-analysis of two trials o
analysis of two trials of ZDV/ddl vs ZDV/ddl/NVP/Patients with hi
-analysis of two trials of vs ZDV/ddl/NVP/Predictors of du
-analysis of two trials of vs ZDV/ddl/NVP/Meta-analysis o
type 1 with zidovudine ( ZDV) treatment/Reduction of maternal-inf
erapy with zidovudine ( ), and didanosine (ddl)/Relationship b
riptor (DLV) + Retrovir ( ) + Epivir (3TC)/Interim analysis of pla
C) 150 mg/zidovudine ( ) 300 mg) given BID plus a protease in
4T + 3TC + IDV versus + 3TC + IDV in treatment naive HIV-inf
d4T + ddl + IDV versus + 3TC + IDV in treatment naive HIV-inf
ched from zidovudine ( ) - containing to stavudine (d4T)-conta
ient use of zidovudine ( ) to reduce perinatal HIV-1 transmissio
nt vs double therapy ( /d4T + 3TC) vs triple therapy (d4T + 3T
ntiviral therapy with 200 mg TID plus ddC 0.75 mg TID ver
sine (DDI), zidovudine ( ) and nevirapine (NVP) can reduce CS
nation with zidovudine ( ) and lamivudine (3TC) in treatment-n
ations with zidovudine ( ), indinavir (IDV) and lamivudine (3TC)
evirapine (NVP)+3TC+ in nucleoside-experienced patients: A
C-442 and zidovudine ( )-lamivudine (3TC), and stavudine (d4
pen-label zidovudine ( ) with lamivudine (3TC) at 36 weeks [D
us EFV + zidovudine ( ) + lamivudine (3TC), versus IDV + ZD
ive either zidovudine ( ) plus lamivudine (3TC) or ZDV plus 3
pen-label zidovudine ( ) and lamivudine (3TC) in HIV-1 infect
experienced patients ( + ddC/ddl) with a low baseline HIV-1 v
avir (IDV), zidovudine ( ), lamivudine (3TC), and stavudine (d4
previously treated with + ddC/Virologic efficacy of 3TC + d4T
g standard zidovudine ( ) prophylaxis/Risk factors for perinatal
d neonatal zidovudine ( ) use in Los Angeles County (LAC)/Mi
w Jersey/Evaluation of administration to pregnant women an
Argentina/Zidovudine ( ) for perinatal prophylaxis starting on w
ans/Use of zidovudine ( ) and pregnancy termination among HI
d adherence of late oral to reduce perinatal HIV transmission,
rial of short-course oral to reduce perinatal HIV transmission,
course oral zidovudine ( ) during late pregnancy/Changes in pl
r, Thailand/Cord blood concentration after intermittent oral ad
evalence of transmitted - and ddl-resistant HIV-1 variants and
+ patients/Zidovudine ( ) phosphorylation determined at interv
erapy with zidovudine ( ) + lamivudine (3TC) in HIV-1 infected
e and with zidovudine ( ) in treatment-naive HIV-1 patients wit
g sustained response to monotherapy/Compartmentalization
V/Effect of zidovudine ( ) administration on liver function of HIV
dovudine-sensitive and zidovudine-resistant HIV-1 isolates in vitr
IV/AIDS in Romania/ Zidovudine plus zalcitabine combination t

act -
60311
60687
60873
14203
43198
43217
13459
60235
42200
32312
22409
12361
12365
12367
12361
12365
12367
12155
12206
129*/12219
12220
12223
12225
12228
12233
12238
12240
12253
12311
12357
12369
12374
22334
22336
22339
22340
22344
22371
22376
462*/23265
458*/23273
23287
23299
23321
32341
30*/33163
33164
33165
41210
509*/42260
60238
60358
60680
60698
41201
12263
23299
23326
33182
509*"/42260
463*"/12152
12155
12156
12157
12184
12197
12206
12220
12228
12233

SKeyword Abstract --
ns of didanosine (DDI), (ZDV) and nevirapine (NVP) c 12253
DV) in combination with (ZDV) and lamivudine (3TC) in 12311
tor, in combination with /3TC/Phase 2 study of ampren 12321
e vs. stavudine alone in experienced, HIV-infected pati 12335
uple combinations with (ZDV), indinavir (IDV) and lami 12357
between MKC-442 and (ZDV)-lamivudine (3TC), and 12374
icaid/Birth defects and use in HIV+ women in New Yo 12376
Impact of indinavir with and lamivudine on the quality 14339
eeks of therapy with, lamivudine and ritonavir (ZLR 21129
nation with open-label (ZDV) with lamivudine (3TC) a 22334
r (IDV), versus EFV + (ZDV) + lamivudine (3TC), ver 22336
men who receive either (ZDV) plus lamivudine (3TC) o 22339
nation with open-label (ZDV) and lamivudine (3TC) in 22340
ns with indinavir (IDV), (ZDV), lamivudine (3TC), and 22371
or in combination with and two dose levels of indinavi 22393
vir in combination with (ZDV/AZT) and zalcitabine (dd 22409
h saquinavir zalcitabine triple combination/Experience 22410
ants receiving standard (ZDV) prophylaxis/Risk factor 462*/23265
esarean delivery with treatment/Decreased perinat 23272
Maternal and neonatal (ZDV) use in Los Angeles Cou 458*/23273
hort-course regimen of to reduce mother-to-child tran 31*/23280
the time of prophylactic /HIV-1 vertical transmission in 23303
natal care and perinatal use to prevent HIV transmissi 23304
sland, Spain/Impact of on perinatal HIV transmission i 23314
480 physicians/Use of (ZDV) and pregnancy terminat 23321
with HIV infection: After /Macrocytosis in patients with 32156
onferring resistance to diminish the virologic respons 32306
ience 1993-1997/Can monotherapy continue to redu 33162
ed to short-course oral (ZDV) during late pregnancy/ 33164
e of a child treated with to reduce vertical HIV1-transm 42125
TMP) levels/Control of phosphorylation: The role of in 42264
tiretroviral therapy with (ZDV) + lamivudine (3TC) in H 60238
ir (IDV) alone and with (ZDV) in treatment-naive HIV- 60358
cted with HCV/Effect of (ZDV) administration on liver f 60698
mpact of treatment with during pregnancy in reducing 60900
tory workers in Harare, Zimbabwe /The relationship of hepatitis B 13301
program in Harare: The AIDS Prevention Project (ZAP 13459
regnancy prevention in /Promoting dual protection for 13562
olence and HIV/AIDS in /Women, violence and HIV/AID 13584
V/AIDS programmes in /Exclusion of homosexuals fro 14247
ctory cohort in Harare, /Low prevalence of active syphi 22197
and HIV transmission in?/Does intravaginal preparatio 23371
male factory workers in /High incidence and prevalenc 23441
vers of AIDS orphans in /Family caregivers of AIDS orp 24207
V/AIDS patients in rural /Family caregivers of HIV/AIDS 24319
IV/STI are feasible in /Clinical trials of vaginal microb 33125
vaginal microbicides in is high/Acceptability of vaginal 33134
n Mexico, the US, and /Men's attitudes toward a poten 33141
mong factory workers in; providing a sustainable HIV pr 540*/33514
ransmission in Mutare, /Peer education to reduce STI/ 533*/33516
ducation programme in /Baseline evaluation of a schoo 41*/33518
nts intervention study in /Perinatal HIV transmission: Et 44124
g in the HIV/AIDS era in /Breast feeding in the HIV/AID 313*/44266
ral Hospital, Bulawayo, /Prevalence of of HIV positive p 60282
) infection in a cohort of Zimbabwean men with high prevalence an 23363
HIV-1 related mortality/ Zinc deficiency profoundly increases risk f 42337
1 seropositive subjects/ supplementation in zinc deficient HIV- 60460
mosexual men/Plasma zinc, copper, and mortality in HIV-1 infecte 12118
o nucleocapsid protein knuckles without affecting cellular zin 41187
Zinc supplementation in deficient HIV-1 seropositive subjects/ 60460
mivudine and ritonavir ( ZLR )/Correlations between immunologic i 21129
mong gay men/Project Zorro: A community led assessment of HI 43189
ith HIV/AIDS/A unique Zululand industry joint venture response t 651*/44221
g injecting drug users in Zurich, Switzerland/Looking beyond need 23352
ut-patient clinics - The Prometheus study/Nelfinavir, dida 42281
Check-in Gesundheit at airport (second phase 1996/1997)/ 60470
tal cohorts/Combining ZVD treatment and elective cesarean secti 23291
onal Chinese medicine: ZY-II recipe for SAIDS treatment/Experim 60048
cyte counts obtained by zymmune and flow cytometry methods/C 42193

n week 24 in Argentina/
egnant women is used/
t exposure prophylaxis/
rienced HIV+ patients/
herapy with nevirapine, zidovudine
ciency virus type 1 with
rapartum and neonatal
etropolitan area/Use of
y HIV-1 infection with a
nfection with nelfinavir,
mbination therapy with
ivudine (3TC) 150 mg/
subjects switched from
on with transient use of

(ZDV) for perinatal prophylaxi
reduces HIV-1 perinatal trans
and combination antiretroviral
(ZDV) phosphorylation deter
and a second nucleoside anal
(ZDV) treatment/Reduction of
treatment in reduction of perin
to reduce the risk of perinatal tr
-resistant strain/CD4 and CD,and lamuvidine/Treatment of
(ZDV), and didanosine (ddl)/
(ZDV) 300 mg) given BID plus
(ZDV) - containing to stavudin
(ZDV) to reduce perinatal HIV